Lilly has unveiled a new operating model and announced a series of changes with the goal of “speed medicines from its pipeline to patients.” The company will establish a Development Center of Excellence (CoE) to streamline and accelerate late-stage development of new medicines, and will reorganize its pharmaceutical business into four business units that will operate alongside the Elanco animal health business unit. In addition, the company has set a goal to reduce its cost structure...